Cited by 300Diabetes Treatment and ManagementRegulation of Appetite and ObesityAdipokines, Inflammation, and Metabolic Diseases

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Effect of Metformin on Glucagon-Like Peptide 1 (GLP-1) and Leptin Levels in Obese Nondiabetic Subjects

Open access

Mannucci, Edoardo, Ognibene, Agostino, Cremasco, Francesco, Bardini, Gianluca, Mencucci, Antonella, Pierazzuoli, Enrica, Ciani, Silvia, Messeri, Gianni, Rotella, Carlo M.·2001·Diabetes Care

DOI 10.2337/diacare.24.3.489

Open this paper in CoChat — free account

Abstract

OBJECTIVE—To evaluate the effects of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels. RESEARCH DESIGN AND METHODS—A total of 10 obese nondiabetic male patients were studied before and after a 14-day treatment with 2,550 mg/day metformin and were compared with 10 untreated obese control subjects. On days 0 and 15, leptin and GLP-1(7–36)amide/(7–37) levels were assessed before and after an oral glucose load during a euglycemic hyperinsulinemic clamp to avoid the interference of variations of insulinemia and glycemia on GLP-1 and leptin secretion. The effects of metformin on GLP-1(7–36)amide degradation in human plasma and in a buffer solution containing dipeptidyl peptidase IV (DPP-IV) were also studied. RESULTS—Leptin levels were not affected by the oral glucose load, and they were not modified after metformin treatment. Metformin induced a significant (P < 0.05) increase of GLP-1(7–36)amide/(7–37) at 30 and 60 min after the oral glucose load (63.8 ± 29.0 vs. 50.3 ± 15.6 pmol/l and 75.8 ± 35.4 vs. 46.9 ± 20.0 pmol/l, respectively), without affecting baseline GLP-1 levels. No variations of GLP-1 levels were observed in the control group. In pooled human plasma, metformin (0.1–0.5 μg/ml) significantly inhibited degradation of GLP-1(7–36)amide after a 30-min incubation at 37°C; similar results were obtained in a buffer solution containing DPP-IV. CONCLUSIONS—Metformin significantly increases GLP-1 levels after an oral glucose load in obese nondiabetic subjects; this effect could be due to an inhibition of GLP-1 degradation.

Integrity signals

Registry

Crossref · 10.2337/diacare.24.3.489

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 916
Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M.-B., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diabetes.44.9.1126 · Cited by 878
Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients
Herrmann, C., Göke, R., Richter, G., Fehmann, H.-C., Arnold, R., & Göke, B. (2009) · Digestion · doi:10.1159/000201231 · Cited by 597
Biguanides and NIDDM
Bailey, C. J. (1992) · Diabetes Care · doi:10.2337/diacare.15.6.755 · Cited by 593
Glucagon-like peptide-1: a potent regulator of food intake in humans
Gutzwiller, J.-P., Göke, B., Drewe, J., Hildebrand, P., Ketterer, S., Handschin, D., Winterhalder, R., Conen, D., & Beglinger, C. (1999) · Gut · doi:10.1136/gut.44.1.81 · Cited by 577
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
Metformin Decreases Food Consumption and Induces Weight Loss in Subjects with Obesity with Type II Non‐Insulin‐Dependent Diabetes
Lee, A., & Morley, J. E. (1998) · Obesity Research · doi:10.1002/j.1550-8528.1998.tb00314.x · Cited by 320
Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus
Mäkimattila, S., Nikkilä, K., & Yki‐Järvinen, H. (1999) · Diabetologia · doi:10.1007/s001250051172 · Cited by 314

Show all 26 references

Sorted by citations

Metformin and the gastrointestinal tract
McCreight, L. J., Bailey, C. J., & Pearson, E. R. (2016) · Diabetologia · doi:10.1007/s00125-015-3844-9 · Cited by 733
Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid–Producing Microbiota in the Gut
de la Cuesta-Zuluaga, J., Mueller, N. T., Corrales-Agudelo, V., Velásquez-Mejía, E. P., Carmona, J. A., Abad, J. M., & Escobar, J. S. (2017) · Diabetes Care · doi:10.2337/dc16-1324 · Cited by 704
Metformin: An Old But Still the Best Treatment for Type 2 Diabetes
Rojas, L. B. A., & Gomes, M. B. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-6 · Cited by 567
Insulin‐associated weight gain in diabetes – causes, effects and coping strategies
Russell-Jones, D. L., & Khan, R. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00686.x · Cited by 569
Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes
Goldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., Williams-Herman, D. E., & for the Sitagliptin 036 Study Group (2007) · Diabetes Care · doi:10.2337/dc07-0627 · Cited by 509
Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes
Kennedy, L. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79145-5 · Cited by 425
Tauroursodeoxycholic Acid May Improve Liver and Muscle but Not Adipose Tissue Insulin Sensitivity in Obese Men and Women
Kars, M., Yang, L., Gregor, M. F., Mohammed, B. S., Pietka, T., Finck, B. N., Patterson, B. W., Horton, J. D., Mittendorfer, B., Hotamışlıgil, G. S., et al. (2010) · Diabetes · doi:10.2337/db10-0308 · Cited by 409
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-Term Pharmacokinetic and 12-Week Dose-Ranging Studies
Buse, J. B., DeFronzo, R. A., Rosenstock, J., Kim, T., Burns, C., Skare, S., Baron, A., & Fineman, M. (2016) · Diabetes Care · doi:10.2337/dc15-0488 · Cited by 325
Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., Eldor, R., & Abdul‐Ghani, M. A. (2013) · Diabetes Care · doi:10.2337/dcs13-2011 · Cited by 323
Metformin
Hundal, R. S., & Inzucchi, S. E. (2003) · Drugs · doi:10.2165/00003495-200363180-00001 · Cited by 315
The Therapeutic Potential of Metformin in Neurodegenerative Diseases
Rotermund, C., Machetanz, G., & Fitzgerald, J. C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00400 · Cited by 316
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
Jadzinsky, M. N., Pfützner, A., Paz-Pacheco, E. T., Xu, Z., Allen, E., Chen, R., & CV181‐039 Investigators (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01056.x · Cited by 294
Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice
Maida, A., Lamont, B. J., Cao, X., & Drucker, D. J. (2010) · Diabetologia · doi:10.1007/s00125-010-1937-z · Cited by 300
Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention
Gottwald‐Hostalek, U., Gwilt, M., & Hildemann, S. K. (2015) · Drugs · doi:10.1007/s40265-015-0416-8 · Cited by 283
Metformin: Is it a drug for all reasons and diseases?
Triggle, C. R., Mohammed, I., Bshesh, K., Marei, I., Ye, K., Ding, H., MacDonald, R. S., Hollenberg, M. D., & Hill, M. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155223 · Cited by 300
Effectiveness of Metformin on Weight Loss in Non-Diabetic Individuals with Obesity
Seifarth, C., Schehler, B., & Schneider, H. (2012) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0032-1327734 · Cited by 258
Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes
Matveyenko, A. V., Dry, S., Cox, H. I., Moshtaghian, A., Gurlo, T., Galasso, R., Butler, A. E., & Butler, P. C. (2009) · Diabetes · doi:10.2337/db09-0058 · Cited by 244
Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes
Green, B. D., Flatt, P. R., & Bailey, C. J. (2006) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2006.024 · Cited by 233
Incretin-Based Therapies in Type 2 Diabetes Mellitus
Chia, C. W., & Egan, J. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2109 · Cited by 223
The Impact of Diabetes and Diabetes Medications on Bone Health
Gilbert, M. P., & Pratley, R. E. (2015) · Endocrine Reviews · doi:10.1210/er.2012-1042 · Cited by 211
Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus
Mannucci, E., Pala, L., Ciani, S., Bardini, G., Pezzatini, A., Sposato, I., Cremasco, F., Ognibene, A., & Rotella, C. M. (2005) · Diabetologia · doi:10.1007/s00125-005-1749-8 · Cited by 206
Self-citation
Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study
Nauck, M. A., Ellis, G. C., Fleck, P. R., Wilson, C. A., Mekki, Q. A., & for the Alogliptin Study 008 Group (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01933.x · Cited by 206
Metformin and digestive disorders
Bouchoucha, M. L., Uzzan, B., & Cohen, R. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.11.002 · Cited by 206
Glycaemic efficacy of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors as add‐on therapy to metformin in subjects with type 2 diabetes—a review and meta analysis
Deacon, C. F., Mannucci, E., & Ahrén, B. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01603.x · Cited by 190
Self-citation
Glycaemic control in type 2 diabetes: Targets and new therapies
Tahrani, A. A., Piya, M. K., Kennedy, A., & Barnett, A. H. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.001 · Cited by 190
Pharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Pοlyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. Α., Katsiki, N., UNDERWOOD, P. C., Park, K., Seufert, J., Kang, E. S., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 196
Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake
Ryskjær, J., Deacon, C. F., Carr, R. D., Krarup, T., Madsbad, S., Holst, J. J., & Vilsbøll, T. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02221 · Cited by 182
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes
Nauck, M. A., & Meier, J. J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.07.014 · Cited by 179
Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1
Migoya, E. M., Bergeron, R., Miller, J., Snyder, R., Tanen, M., Hilliard, D., Weiss, B., Larson, P., Gutierrez, M., Jiang, G., et al. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.184 · Cited by 177
Bodyweight Changes Associated with Antihyperglycaemic Agents in Type 2 Diabetes Mellitus
Hermansen, K., & Mortensen, L. S. (2007) · Drug Safety · doi:10.2165/00002018-200730120-00005 · Cited by 173
New mechanisms of metformin action: Focusing on mitochondria and the gut
Hur, K. Y., & Lee, M. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12328 · Cited by 161
Mechanisms Underlying Metformin-Induced Secretion of Glucagon-Like Peptide-1 from the Intestinal L Cell
Mulherin, A. J., Oh, A., Kim, H., Grieco, A. J., Lauffer, L. M., & Brubaker, P. L. (2011) · Endocrinology · doi:10.1210/en.2011-1485 · Cited by 158
Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes
Lindsay, J. R., Duffy, N. A., McKillop, A. M., Ardill, J. E. S., O'Harte, F. P. M., Flatt, P. R., & Bell, P. M. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01461.x · Cited by 158
Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes
Aschner, P. J., Katzeff, H. L., Guo, H., Sunga, S., Williams‐Herman, D., Kaufman, K. D., Goldstein, B. J., & for the Sitagliptin Study 049 Group (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01187.x · Cited by 158
Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes
Williams‐Herman, D., JOHNSON, J. R., Teng, R., Golm, G. T., Kaufman, K. D., Goldstein, B. J., & Amatruda, J. M. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01204.x · Cited by 154
Pharmacotherapy of type 2 diabetes: An update and future directions
DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 173
Metformin for Weight Loss and Metabolic Control in Overweight Outpatients With Schizophrenia and Schizoaffective Disorder
Jarskog, L. F., Hamer, R. M., Catellier, D. J., Stewart, D. D., LaVange, L., Ray, N., Golden, L. H., Lieberman, J. A., Stroup, T. S., & for the METS Investigators (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12010127 · Cited by 145
Enhanced secretion of glucagon-like peptide 1 by biguanide compounds
Yasuda, N., Inoue, T., Nagakura, T., Yamazaki, K., Kira, K., Saeki, T., & Tanaka, I. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02565-2 · Cited by 137
Metformin: A review of its therapeutic efficacy and adverse effects
Shurrab, N. T., & Arafa, E. A. (2020) · Obesity Medicine · doi:10.1016/j.obmed.2020.100186 · Cited by 145
Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study
Williams‐Herman, D., Johnson, J. R., Teng, R., Luo, E., Davies, M. J., Kaufman, K. D., Goldstein, B. J., & Amatruda, J. M. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990802705679 · Cited by 126
Overview of food products and dietary constituents with antidiabetic properties and their putative mechanisms of action: A natural approach to complement pharmacotherapy in the management of diabetes
Lacroix, I. M. E., & Li‐Chan, E. C. Y. (2013) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201300223 · Cited by 127
Metformin for clozapine associated obesity: a systematic review and meta-analysis
Siskind, D. J., Leung, J., Russell, A. W., Wysoczanski, D., & Kisely, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156208 · Cited by 122
The effect of metformin on food intake and its potential role in hypothalamic regulation in obese diabetic rats
Lv, W., Wen, J., Li, L., Sun, R., Wang, J., Xian, Y., Cao, C., Wang, Y., & Gao, Y. (2012) · Brain Research · doi:10.1016/j.brainres.2012.01.028 · Cited by 118
Metformin: Therapeutic profile in the treatment of type 2 diabetes
Bailey, C. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15663 · Cited by 143
Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1
Green, B. D., Irwin, N., Duffy, N. A., Gault, V. A., O'Harte, F. P. M., & Flatt, P. R. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.07.043 · Cited by 116
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients
Derosa, G., Maffioli, P., SALVADEO, S. A. T., Ferrari, I., Ragonesi, P. D., Querci, F., Franzetti, I., Gadaleta, G., Ciccarelli, L., Piccinni, M. N., et al. (2009) · Metabolism · doi:10.1016/j.metabol.2009.10.007 · Cited by 113
Role of Metformin for Weight Management in Patients Without Type 2 Diabetes
Desilets, A. R., Dhakal-Karki, S., & Dunican, K. C. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1k656 · Cited by 111
Metformin Effects on Dipeptidylpeptidase IV Degradation of Glucagon-like Peptide-1
Hinke, S. A., Kühn‐Wache, K., Hoffmann, T., Pederson, R. A., McIntosh, C. H. S., & Demuth, H. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6607 · Cited by 103
Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin
Bolli, G. B., Dotta, F., Colin, L., Minic, B., & Goodman, M. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.01023.x · Cited by 105
Glucagon‐like Peptide‐2 and the Regulation of Intestinal Growth and Function
Brubaker, P. L. (2018) · Comprehensive physiology · doi:10.1002/cphy.c170055 · Cited by 132
Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes
D'Alessio, D. A., Denney, A. M., Hermiller, L. M., Prigeon, R. L., Martin, J. M., Tharp, W. G., Saylan, M. L., He, Y., Dunning, B. E., Foley, J. E., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1135 · Cited by 99
Profiles of Circulating miRNAs Following Metformin Treatment in Patients with Type 2 Diabetes
Demirsoy, İ. H., Ertural, D. Y., Balcı, Ş., Çınkır, Ü., Sezer, K., Tamer, L., & Aras, N. (2018) · Journal of Medical Biochemistry · doi:10.2478/jomb-2018-0009 · Cited by 98
Structure and function studies of glucagon‐like peptide‐1 (GLP‐1): the designing of a novel pharmacological agent for the treatment of diabetes
Hui, H., Zhao, X., & Perfetti, R. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.553 · Cited by 99
Metabolic Effects of Metformin in the Failing Heart
Dziubak, A., Wójcicka, G., Wojtak, A., & Bełtowski, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102869 · Cited by 99
Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes
Herman, G. A., Bergman, A. J., Yi, B., Kipnes, M. S., & for the Sitagliptin Study 012 Group (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x132587 · Cited by 96
Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes
Åhrén, B. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210802584126 · Cited by 95
Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial
Jensterle, M., Kravos, N. A., Goričar, K., & Janez, A. (2017) · BMC Endocrine Disorders · doi:10.1186/s12902-017-0155-9 · Cited by 93
The Relationships between Gut Microbiota and Diabetes Mellitus, and Treatments for Diabetes Mellitus
Crăciun, C.-I., Neag, M. A., Cătinean, A., Mitre, A. O., Rusu, A., Bala, C. G., Román, G., Buzoianu, A. D., Muntean, D. M., & Craciun, A. E. (2022) · Biomedicines · doi:10.3390/biomedicines10020308 · Cited by 95
Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments
Lenhard, J. M., Croom, D. K., & Minnick, D. T. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.09.021 · Cited by 90
New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser
Cho, Y. M., & Kieffer, T. J. (2010) · Diabetologia · doi:10.1007/s00125-010-1986-3 · Cited by 91
Mechanisms of action of metformin with special reference to cardiovascular protection
Zilov, A. V., Abdelaziz, S. I., Alshammary, A., Zahrani, A. A., Amir, A., Khalil, S. H. A., Brand, K. M. G., Elkafrawy, N., Hassoun, A. A. K., Jahed, S. A., et al. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3173 · Cited by 89
Metformin induces significant reduction of body weight, total cholesterol and LDL levels in the elderly – A meta-analysis
Solymár, M., Ivić, I. D., Pótó, L., Hegyi, P. J., Garami, A., Hartmann, P., Pétervári, E., Czopf, L., Hussain, A., Gyöngyi, Z., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207947 · Cited by 86
Effects of the brown rice diet on visceral obesity and endothelial function: the BRAVO study
Shimabukuro, M., Higa, M., Kinjo, R., Yamakawa, K., Tanaka, H., Kozuka, C., Yabiku, K., Taira, S.-I., Sata, M., & Masuzaki, H. (2013) · British Journal Of Nutrition · doi:10.1017/s0007114513002432 · Cited by 86
Lac-Phe mediates the effects of metformin on food intake and body weight
Xiao, S., Li, V. L., Lyu, X., Chen, X., Wei, W., Abbasi, F., Knowles, J. W., Tung, A. S.-H., Deng, S., Tiwari, G., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-00999-9 · Cited by 85
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin
Åhrén, B. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1944 · Cited by 84
Metformin in therapeutic applications in human diseases: its mechanism of action and clinical study
Du, Y., Zhu, Y., Zhou, Y., Ding, J., & Liu, J. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00108-w · Cited by 84
Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity
Anandhakrishnan, A., & Korbonits, M. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i20.572 · Cited by 83
Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers
Fiedorowicz, J. G., Miller, D. D., Bishop, J. R., Calarge, C. A., Ellingrod, V. L., & Haynes, W. G. (2012) · Current Psychiatry Reviews · doi:10.2174/157340012798994867 · Cited by 82
Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes
El Bekay, R., Coín‐Aragüez, L., Fernández‐García, D., Oliva‐Olivera, W., Bernal‐López, R., Clemente‐Postigo, M., Delgado‐Lista, J., Diaz‐Ruiz, A., Guzman‐Ruiz, R., Vázquez‐Martínez, R., et al. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13481 · Cited by 78
Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells
Pala, L., Mannucci, E., Pezzatini, A., Ciani, S., Sardi, J., Raimondi, L., Ognibene, A., Cappadona, A., Vannelli, B., & Rotella, C. M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.08.111 · Cited by 76
Self-citation
Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet
Schweizer, A. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s2503 · Cited by 77
Orlistat Augments Postprandial Increases in Glucagon-like Peptide 1 in Obese Type 2 Diabetic Patients
Damcı, T., Yalın, S., Balcı, H., Oşar, Z., Korugan, Ü., Özyazar, M., & ILKOVA, H. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1077 · Cited by 75
A story of metformin-butyrate synergism to control various pathological conditions as a consequence of gut microbiome modification: Genesis of a wonder drug?
Maniar, K., Moideen, A., Mittal, A., Patil, A., Chakrabarti, A., & Banerjee, D. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.12.003 · Cited by 75
Involvement of glucagon‐like peptide‐1 in the glucose‐lowering effect of metformin
Bahne, E., Hansen, M., Brønden, A., Sonne, D. P., Vilsbøll, T., & Knop, F. K. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12697 · Cited by 73
Metformin Reduces Body Weight Gain and Improves Glucose Intolerance in High-Fat Diet-Fed C57BL/6J Mice
Matsui, Y., Hirasawa, Y., Sugiura, T., Toyoshi, T., Kyuki, K., & Ito, M. (2010) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.33.963 · Cited by 71
Novel agents for the treatment of type 2 diabetes
DeFronzo, R. A., Triplitt, C. L., Abdul-Ghani, M., & Cersosimo, E. (2014) · Diabetes Spectrum · doi:10.2337/diaspect.27.2.100 · Cited by 83
View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences
Froldi, G. (2024) · Pharmaceuticals · doi:10.3390/ph17040478 · Cited by 75
Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability
Ito, H., Nishio, S., & Abe, M. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s54679 · Cited by 70
Dipeptidyl Peptidase IV Inhibitors and the Incretin System in Type 2 Diabetes Mellitus
Langley, A., Suffoletta, T. J., & Jennings, H. R. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.8.1163 · Cited by 65
A brief glimpse at CTRP3 and CTRP9 in lipid metabolism and cardiovascular protection
Yang, Y., Li, Y., Ma, Z., Jiang, S., Fan, C., Hu, W., Wang, D., Di, S., Sun, Y., & Yi, W. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2016.10.001 · Cited by 67
Prebiotic Fiber Increases Hepatic Acetyl CoA Carboxylase Phosphorylation and Suppresses Glucose-Dependent Insulinotropic Polypeptide Secretion More Effectively When Used with Metformin in Obese Rats,
Pyra, K. A., Saha, D. C., & Reimer, R. A. (2012) · Journal of Nutrition · doi:10.3945/jn.111.147132 · Cited by 69
Metformin Causes Reduction of Food Intake and Body Weight Gain and Improvement of Glucose Intolerance in Combination with Dipeptidyl Peptidase IV Inhibitor in Zucker fa/fa Rats
Yasuda, N., Inoue, T., Nagakura, T., Yamazaki, K., Kira, K., Saeki, T., & Tanaka, I. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.064964 · Cited by 63
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes
Mikhail, N. E. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.6.845 · Cited by 63
Effects of metformin on energy intake and satiety in obese children
Adeyemo, M. A., McDuffie, J. R., Kozlosky, M., Krakoff, J. A., Calis, K. A., Brady, S. M., & Yanovski, J. A. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12426 · Cited by 61
Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes
Solis‐Herrera, C., Triplitt, C. L., Garduño‐García, J. D. J., Adams, J., DeFronzo, R. A., & Cersósimo, E. (2013) · Diabetes Care · doi:10.2337/dc12-2072 · Cited by 61
Sustained influence of metformin therapy on circulating glucagon‐like peptide‐1 levels in individuals with and without type 2 diabetes
Preiss, D., Dawed, A. Y., Welsh, P. I., Heggie, A. J., Jones, A. G., Dekker, J., Koivula, R. W., Hansen, T. H., Stewart, C., Holman, R. R., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12826 · Cited by 61
Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects
McKillop, A. M., Duffy, N. A., Lindsay, J. R., O'Harte, F. P. M., Bell, P. M., & Flatt, P. R. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.08.001 · Cited by 58
Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects
Graefe-Mody, E. U., Padula, S. J., Ring, A., Withopf, B., & Dugi, K. A. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903094361 · Cited by 57
Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study
JENSTERLE, M., GORICAR, K., & JANEZ, A. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3081 · Cited by 56
Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk
Mannucci, E., & Rotella, C. M. (2008) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.08.002 · Cited by 57
Self-citation
Effect of Serotonin Transporter 5-HTTLPR Polymorphism on Gastrointestinal Intolerance to Metformin: A GoDARTS Study
Dujić, T., Zhou, K., Tavendale, R., Palmer, C. N. A., & Pearson, E. R. (2016) · Diabetes Care · doi:10.2337/dc16-0706 · Cited by 56
Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective
Deacon, C. F., & Holst, J. J. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00359-5 · Cited by 55
Metformin inhibits leptin secretion via a mitogen-activated protein kinase signalling pathway in brown adipocytes
Klein, J. C., Westphal, S., Kraus, D., Meier, B., Perwitz, N., Ott, V., Faßhauer, M., & Klein, H. H. (2004) · Journal of Endocrinology · doi:10.1677/joe.1.05646 · Cited by 53
Metformin: an old therapy that deserves a new indication for the treatment of obesity.
Igel, L. I., Sinha, A., Saunders, K. H., Apovian, C. M., Vojta, D., & Aronne, L. J. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0568-3 · Cited by 52
A randomized, triple masked, placebo-controlled clinical trial for controlling childhood obesity
Rezvanian, H., Hashemipour, M., Kelishadi, R., Tavakoli, N., & Poursafa, P. (2010) · World Journal of Pediatrics · doi:10.1007/s12519-010-0232-x · Cited by 52
Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis
Hui, F., Zhang, Y., Ren, T., Li, X., Zhao, M., & Zhao, Q. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2593-3 · Cited by 55
Role of thiazolidinediones, insulin sensitizers, in non‐alcoholic fatty liver disease
Chang, E., Park, C., & Park, S. W. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12107 · Cited by 52
Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells
Krizhanovskii, C., Patrone, C., Holst, J. J., Zhang, Q., & Sjöholm, Å. (2012) · Journal of Gastroenterology · doi:10.1007/s00535-012-0637-5 · Cited by 51
Inhibition of dipeptidyl peptidase IV activity as a therapy of Type 2 diabetes
Green, B. D., Flatt, P. R., & Bailey, C. J. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.3.525 · Cited by 50

Authors: Mannucci, E., Ognibene, A., Cremasco, F., Bardini, G., Mencucci, A., Pierazzuoli, E., Ciani, S., Messeri, G., & Rotella, C. M.
Affiliations: University of Florence (IT)
Azienda Ospedaliero-Universitaria Careggi (IT)
Corresponding author: Rotella, Carlo M.
ORCID: Mannucci, Edoardo
Ognibene, Agostino
Messeri, Gianni
Rotella, Carlo M.
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2001-03-01
Volume: 24
Issue: 3
Pages: 489-494
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/diacare.24.3.489
OpenAlex: W2157841460
Cited by: 300
References: 26
Citations by year: 2026: 5 · 2025: 6 · 2024: 11 · 2023: 6 · 2022: 10 · 2021: 8 · 2020: 6 · 2019: 11 · 2018: 17 · 2017: 20 · 2016: 24 · 2015: 12 · 2014: 14 · 2013: 26 · 2012: 18
FWCI: 3.46
Type: journal article
Language: en
Open access: green
www.openaccessrepository.it
Licence: other-oa
Locations: Diabetes Care (publishedVersion)
PubMed (publishedVersion)
Florence Research (University of Florence) (submittedVersion)
INFM-OAR (INFN Catania) (submittedVersion, other-oa)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords: metformin, glucagon-like peptide-1, leptin, obesity, GLP-1(7-36)amide, dipeptidyl peptidase IV, oral glucose load, hyperinsulinemic-euglycemic clamp, incretin secretion
MeSH terms: Adolescent, Adult, Blood Glucose, Glucagon-Like Peptides, Glucagon, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Obesity, Peptide Fragments, Peptides, Glucose Clamp Technique, Leptin, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of Metformin on Glucagon-Like Peptide 1 (GLP-1) and Leptin Levels in Obese Nondiabetic Subjects

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks